Company intelligence / Profile preview

Lauro Cinquantesette S.p.A.

Italy

Ownership: Private
Development stage: Other

Overview

Lauro Cinquantesette S.p.A. was a private equity-backed holding company that owned Prime European Therapeuticals S.p.A. (Euticals), a global Active Pharmaceutical Ingredient (API) manufacturer. In 2016, Lauro 57 facilitated the sale of Euticals to AMRI, receiving AMRI shares and a seller note. Following this divestiture, Lauro 57 appears to be defunct.

Industry: Investors

Partnerships

Clessidra Capital Partners IIMandarin Capital Partners SCA SICARPrivate Equity Partners SGRIdea Capital Funds SGR

Beyond the preview

Go deeper on Lauro Cinquantesette S.p.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lauro Cinquantesette S.p.A..

Explore the full profile